Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Apolipoprotein L

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    112 result(s) found for: Apolipoprotein L. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-003626-26 Sponsor Protocol Number: 01-05-TL-475-016 Start Date*: 2006-06-14
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous f...
    Medical condition: Treatment of primary dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024064-18 Sponsor Protocol Number: OM-EPA-003 Start Date*: 2011-03-22
    Sponsor Name:Omthera Pharmaceutical Inc.
    Full Title: Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia
    Medical condition: Severe hypertriglyceridemia defined as serum triglyceride (TG) values ≥500 and <2000 mg/dL (≥5.65 mmol/L and <22.60 mmol/L).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002316-24 Sponsor Protocol Number: TAK-475/EC304 Start Date*: 2005-09-27
    Sponsor Name:Takeda Europe R &D Centre Ltd
    Full Title: A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.
    Medical condition: treatment of patients with primary dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 pt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) EE (Completed) SK (Completed) CZ (Completed) DE (Completed) DK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-005924-16 Sponsor Protocol Number: M13-377 Start Date*: 2012-06-13
    Sponsor Name:Abbott Laboratories Ireland Limited
    Full Title: A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching M...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005643-24 Sponsor Protocol Number: TA-8995-03 Start Date*: 2013-07-29
    Sponsor Name:Xention Limited
    Full Title: A Multi-Centre, Randomised, Double Blind, Placebo Controlled, Parallel Group Study of TA 8995 in Patients with Mild Dyslipidaemia, Alone and In Combination with Statin Therapy
    Medical condition: Mild dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10020049 High cholesterol LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001934-19 Sponsor Protocol Number: LPS14354 Start Date*: 2016-02-15
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Ris...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000622-55 Sponsor Protocol Number: I5S-MC-EFJE Start Date*: 2013-07-31
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia
    Medical condition: Primary hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000893-68 Sponsor Protocol Number: LAED001 Start Date*: 2012-11-15
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: Differences in endothelial function amongst Sitagliptin and Liraglutide Users: A randomized, open-label, parallel-group and active controlled trial
    Medical condition: type 2 diabetes patients not well controlled at the maximum tolerated dose of metformin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001109-29 Sponsor Protocol Number: CKJX839D12304 Start Date*: 2022-12-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients with Primary Hypercholesterolemia Not Receiving Lipid-L...
    Medical condition: Primary Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10077965 Primary hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002315-25 Sponsor Protocol Number: TAK-475/EC303 Start Date*: 2005-12-15
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezet...
    Medical condition: Treatment of patients with primary dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) FI (Completed) LV (Completed) LT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005469-20 Sponsor Protocol Number: DRI6589 Start Date*: 2007-02-15
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled, ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of four doses and two dose-regimens of AVE5530 over 4 week...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-003511-75 Sponsor Protocol Number: WEL-410 Start Date*: 2005-10-18
    Sponsor Name:Sankyo Pharma Development (SPhD)
    Full Title: Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients with Heterozygous Familial Hypercholesterolemia on a Stable Dose of Stat...
    Medical condition: Pediatric Heterozygous Familial Hypercholesterolemia (heFH)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10057079 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) NO (Ongoing) HU (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-001489-34 Sponsor Protocol Number: TAK-475_306 Start Date*: 2007-10-01
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd
    Full Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg versus Placebo in Subjects with Hypercholesterolemia, With an Optional Open-Label Extension
    Medical condition: Subjects With Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Completed) EE (Prematurely Ended) HU (Prematurely Ended) ES (Completed) NL (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004413-33 Sponsor Protocol Number: KBT-004 Start Date*: 2007-10-26
    Sponsor Name:Karo Bio AB
    Full Title: A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB 2115 as add on to Statin Treatment in Patients With Dyslipid...
    Medical condition: Primary hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020603 Hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-005399-40 Sponsor Protocol Number: 20110233 Start Date*: 2012-03-09
    Sponsor Name:Amgen Inc
    Full Title: A two part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia Part A - Open-label, Single-arm, Multicenter Pilot...
    Medical condition: Homozygous familial hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10057100 Homozygous familial hypercholesterolaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) ES (Completed) IT (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003755-21 Sponsor Protocol Number: ISIS304801-CS7 Start Date*: 2016-06-06
    Sponsor Name:Akcea Therapeutics
    Full Title: An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10017339 Fredrickson Type I lipidaemia LLT
    20.0 100000004850 10060593 Fredrickson Type I lipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002510-38 Sponsor Protocol Number: D3569C00007 Start Date*: 2005-12-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, 52-Week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excreti...
    Medical condition: Male and female patients aged >= 18 and <=70 years with Type 1 or 2 diabetes, moderate proteinuria (baseline urinary protein/creatinine ratio >=500 mg/g and <=5000 mg/g), mild hypercholesterolaemia...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002276-25 Sponsor Protocol Number: 20120124 Start Date*: 2016-10-21
    Sponsor Name:Amgen Inc
    Full Title: Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects Fr...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10057100 Homozygous familial hypercholesterolaemia LLT
    18.1 100000004850 10057099 Heterozygous familial hypercholesterolaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) HU (Completed) AT (Completed) BE (Completed) CZ (Completed) GR (Completed) ES (Completed) NL (Completed) PT (Completed) SI (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-000799-92 Sponsor Protocol Number: LPS14355 Start Date*: 2015-12-31
    Sponsor Name:sanofi-aventis Groupe
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hyperchole...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) AT (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007831-24 Sponsor Protocol Number: KBT-006 Start Date*: 2008-03-17
    Sponsor Name:Karo Bio AB
    Full Title: A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB2115 as add on to Ezetimibe treatment in Patients with Primary...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020603 Hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 14:44:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA